Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Pharma, Inc.

76.59
-0.0100-0.01%
Post-market: 75.88-0.7100-0.93%16:15 EDT
Volume:2.05M
Turnover:155.95M
Market Cap:15.00B
PE:-21.46
High:77.24
Open:76.20
Low:75.02
Close:76.60
52wk High:93.42
52wk Low:48.78
Shares:195.81M
Float Shares:167.00M
Volume Ratio:1.41
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5686
EPS(LYR):-3.7850
ROE:-1789.67%
ROA:-26.00%
PB:-5.96
PE(LYR):-20.24

Loading ...

BridgeBio Oncology awards employee stock options for 32,675 shares at $7.66

Reuters
·
May 13

BridgeBio shares have ‘clear path’ to $90s, says JPMorgan

TIPRANKS
·
May 12

BRIEF-Bridgebio Submits NDA To FDA For Encaleret For Individuals Living With ADH1

Reuters
·
May 12

BridgeBio Files New Drug Application for Rare Calcium Disorder Treatment

MT Newswires Live
·
May 12

BridgeBio submits FDA NDA for encaleret to treat autosomal dominant hypocalcemia type 1

Reuters
·
May 12

BridgeBio Submits Nda to FDA for Encaleret for Individuals Living With Adh1

THOMSON REUTERS
·
May 12

BridgeBio Pharma Inc - Encaleret May Be Eligible for Priority Review; U.S. Launch Anticipated Early 2027

THOMSON REUTERS
·
May 12

BridgeBio Pharma Inc - to Initiate Phase 3 Reclaim-HP Study of Encaleret in Chronic Hypoparathyroidism Summer 2026

THOMSON REUTERS
·
May 12

BridgeBio Pharma Inc - to Submit Maa to Ema for Encaleret in Adh1 in Second Half 2026

THOMSON REUTERS
·
May 12

BridgeBio publishes Phase 3 CALIBRATE trial presentation for encaleret in ADH1

Reuters
·
May 12

BridgeBio CEO Neil Kumar disposes of common shares worth $5.48 million

Reuters
·
May 12

BridgeBio announces new data of Phase 3 ATTRibute-CM study at Heart Failure 2026

TIPRANKS
·
May 12

BridgeBio posts acoramidis ATTRibute-CM KCCQ subgroup data presentation

Reuters
·
May 11

BridgeBio posts ESC-HF presentation on acoramidis impact on NT-proBNP in ATTR-CM

Reuters
·
May 11

BridgeBio publishes acoramidis-versus-tafamidis ATTR-CM analysis presentation

Reuters
·
May 11

BRIEF-Acoramidis Continues To Demonstrate Disease-Modifying Effects In ATTR-CM

Reuters
·
May 11

BridgeBio says acoramidis cuts outpatient worsening heart failure risk 41% in Phase 3 trial

Reuters
·
May 11

Acoramidis Continues to Demonstrate Disease-Modifying Effects in Attr-Cm, Reducing Sttr Variability and Outpatient Worsening Heart Failure

THOMSON REUTERS
·
May 11

BridgeBio Pharma Inc - Acoramidis Reduces Cardiovascular Hospitalizations by 34% Versus Tafamidis

THOMSON REUTERS
·
May 11

BridgeBio Pharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 11